Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.69 |
| ▸ | MEN1 | O00255 | 9/20 | 0.69 |
| ▸ | MAPT | P10636 | 5/20 | 0.69 |
| ▸ | RAB9A | P51151 | 5/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.69 |
| ▸ | HPGD | P15428 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 3/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9003760 | 0.87 | NPC1 (0.76) | NPC1KMT2AMEN1MAPTRAB9A | |
| SCHEMBL2301276 | 0.85 | NPC1 (0.74) | NPC1KMT2AMEN1MAPTRAB9A | |
| SCHEMBL25327546 | 0.84 | MEN1 (0.84) | NPC1KMT2AMEN1MAPTRAB9A | |
| SCHEMBL10719391 | 0.84 | NPC1 (0.73) | NPC1KMT2AMEN1MAPTRAB9A | |
| SCHEMBL3385712 | 0.84 | NPC1 (0.73) | NPC1KMT2AMEN1MAPTRAB9A | |
| SCHEMBL4197234 | 0.83 | NPC1 (0.71) | NPC1KMT2AMEN1MAPTRAB9A | |
| SCHEMBL747850 | 0.83 | NPC1 (0.71) | NPC1KMT2AMEN1MAPTRAB9A | |
| SCHEMBL312323 | 0.83 | NPC1 (0.71) | NPC1KMT2AMEN1MAPTRAB9A | |
| SCHEMBL153386 | 0.83 | ALDH1A1 (0.76) | NPC1KMT2AMAPTLMNAALDH1A1 | |
| Avobenzone SCHEMBL6129882 | 0.83 | LMNA (0.71) | NPC1KMT2AMEN1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5877210-A | CONTROLLING IMMUNE RESPONSE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-02 | — | — | US | claimed |
| US-5583242-A | VANADYL COMPLEXES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-10 | — | — | US | claimed |
| US-5565491-A | FOR TREATMENT OF DISEASES MARKED BY MALIGNANT PROLIFERATION OF B CELLS, SUCH AS LEUKEMIA AND LYMPHOMAS; ANTICARCINOGENIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-15 | — | — | US | claimed |
| US-20230241078-A1 | Vanadyl and vanadate for use in reducing stress-induced metabolic derangement | CFM PHARMA HOLDING B.V. (NL) | 2023-08-03 | — | — | US | disclosed |
| US-20200246352-A1 | Vanadyl and vanadate for use in reducing stress-induced metabolic derangement | CFM PHARMA HOLDING B.V. (NL) | 2020-08-06 | — | — | US | disclosed |
| EP-3684352-A1 | VANADYL AND VANADATE FOR USE IN REDUCING STRESS -INDUCED METABOLIC DERANGEMENT | CFM Pharma Holding BV (NL) | 2020-07-29 | — | — | EP | disclosed |
| CN-111343977-A | Vanadyl and vanadate bases for reducing stress-induced metabolic disorders | CFM医药控股有限公司 | 2020-06-26 | — | — | CN | disclosed |
| WO-2019059770-A1 | VANADYL AND VANADATE FOR USE IN REDUCING STRESS -INDUCED METABOLIC DERANGEMENT | CFM PHARMA HOLDING B.V. (NL) | 2019-03-28 | — | — | WO | disclosed |
| US-8242130-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| EP-1838296-B1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP (CA) | 2012-08-08 | — | — | EP | disclosed |
| US-8093273-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-01-10 | — | — | US | disclosed |
| US-6413998-B1 | BONE REGENERATION | OSTEOSCREEN, INC. | 2002-07-02 | — | — | US | disclosed |
| US-6008208-A | Compositions and methods for treating bone deficit conditions | OSTEOSCREEN, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| US-5877210-A | CONTROLLING IMMUNE RESPONSE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-02 | — | — | US | disclosed |
| US-5846998-A | Use of phosphotyrosine phosphatase inhibitors or phosphotyrosine kinase activators for controlling cellular proliferation | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-12-08 | — | — | US | disclosed |
| US-5693627-A | TREATING DISEASES SUCH AS LEUKEMIAS AND LYMPHOMAS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| US-5583242-A | VANADYL COMPLEXES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| US-5565491-A | FOR TREATMENT OF DISEASES MARKED BY MALIGNANT PROLIFERATION OF B CELLS, SUCH AS LEUKEMIA AND LYMPHOMAS; ANTICARCINOGENIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0735880-A1 | USE OF VANADIUM MOLYBDENUM OR TUNGSTEN COMPLEXES FOR CONTROLLING CELLULAR PROLIFERATION | Bristol-Myers Squibb Company (US) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995020390-A1 | USE OF VANADIUM MOLYBDENUM OR TUNGSTEN COMPLEXES FOR CONTROLLING CELLULAR PROLIFERATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-08-03 | — | — | WO | disclosed |